Financial Performance - The company reported a significant decline in basic earnings per share, dropping to 0.0187 yuan in Q1 2025 from 0.2326 yuan in Q1 2024, representing a decrease of 91.96% [1] - Net profit for Q1 2025 was 0.08 billion yuan, down 92% from 1 billion yuan in Q1 2024 [1] - Revenue decreased to 4.3 billion yuan in Q1 2025, a decline of 10.23% compared to 4.79 billion yuan in Q1 2024 [1] - The return on equity fell to 0.26% in Q1 2025 from 3.13% in Q1 2024, marking a decrease of 91.69% [1] Shareholder Information - The top ten unrestricted shareholders collectively hold 98.7644 million shares, accounting for 22.83% of the circulating shares, with a decrease of 2.2972 million shares compared to the previous period [1] - Major shareholders include Chen Zhiqiang and Wu Kunxiang, each holding 23.9313 million shares, representing 5.53% of the total share capital, with no change in their holdings [2] - The Hong Kong Central Clearing Limited reduced its holdings by 2.1367 million shares, now holding 5.6405 million shares, which is 1.30% of the total share capital [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [3]
开立医疗:2025一季报净利润0.08亿 同比下降92%